First Trust Nasdaq Pharmaceuticals ETF FTXH
43.40 USD -0.41 (-0.93%)
Regular-session close
43.45 +0.05 +0.11%
After hours · Nov 17, 4:00 PM ET
43.24 Day range 43.59
31.42 52-week range 45.10
- YTD
- +31.76%
- 1 year
- +37.61%
News
zacks.com Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now? The First Trust NASDAQ Pharmaceuticals ETF (FTXH) was launched on 09/20/2016, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
zacks.com Should You Invest in the First Trust NASDAQ Pharmaceuticals ETF (FTXH)? Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the First Trust NASDAQ Pharmaceuticals ETF (FTXH), a passively managed exchange traded fund…
zacks.com Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now? The First Trust NASDAQ Pharmaceuticals ETF (FTXH) was launched on 09/20/2016, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
zacks.com Should You Invest in the First Trust NASDAQ Pharmaceuticals ETF (FTXH)? Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the First Trust NASDAQ Pharmaceuticals ETF (FTXH) is a passively managed exchange traded fund launched on…
reuters.com Trump to announce discount drug pricing expansion, White House official says U.S. President Donald Trump will announce a dramatic expansion of TrumpRx.gov, a government-backed website offering discounted prescription drugs under his administration's pricing deal, on Monday,…
marketwatch.com Could pressure to make money faster kill the next lifesaving pill? When activist investors take a stake in a pharmaceutical company, markets often cheer. The expectation is leaner operations, sharper strategy and higher stock prices.
zacks.com Pharma ETF (FTXH) Hits New 52-Week High Pharma ETF FTXH hits a new 52-week high as industry momentum, rate cuts, and AI adoption lift the sector???signaling potential near-term upside for FTXH investors.
fastcompany.com Trump announces 100% tariffs on pharmaceutical drugs, beginning October 1 President Donald Trump said Thursday that he will put import taxes of 100% on pharmaceutical drugs, 50% on kitchen cabinets and bathroom vanities, 30% on upholstered furniture and 25% on heavy trucks…
zacks.com Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.
zacks.com A Look at Pharma ETFs After Strong Q1 Earnings Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.
zacks.com Pharma ETFs in Focus Post Solid Q2 Earnings Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
zacks.com A Look at Pharma ETFs Post Q1 Earnings Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
zacks.com JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.
zacks.com A Look at Pharma ETFs After Q4 Earnings The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs…
zacks.com Pharma ETFs in Focus Post Q3 Earnings Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
zacks.com Pharma ETFs in Focus Post Q2 Earnings Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.
zacks.com 5 ETFs to Buy on JNJ's Q2 Earnings Strength Johnson & Johnson (JNJ) continued with its long streak of earnings beat. It topped the revenue estimate as well as lifted the full-year outlook.
zacks.com Biotech ETFs in Focus on Covid Vaccines' Fall Rollout The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.
zacks.com Pharma ETFs Gain Post Q1 Earnings Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. As such, pharma ETFs have been in the green over the past month.
seekingalpha.com Can Health Care Stocks Outperform Again In 2023? How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.
